Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30376225 | 1.00 | HTT (0.64) | HTTCYP1A1CYP1A2CYP1B1TYMS | |
| SCHEMBL29441517 | 0.81 | HTT (0.68) | HTTHTR3AHRH4ALDH1A1 | |
| SCHEMBL21500731 | 0.81 | HTT (0.68) | HTTHTR3AHRH4ALDH1A1 | |
| SCHEMBL1069650 | 0.81 | HTT (0.41) | HTTTYMSAPPKDM4EALDH1A1 | |
| SCHEMBL5360039 | 0.81 | DCPS (0.53) | — | |
| SCHEMBL8897424 | 0.78 | HTT (1.00) | HTTCYP1A2 | |
| SCHEMBL8900878 | 0.78 | HTT (0.64) | HTTTYMS | |
| SCHEMBL29767521 | 0.78 | APP (0.42) | HTTCYP1A1CYP1A2CYP1B1TYMS | |
| SCHEMBL1069686 | 0.78 | HTT (0.39) | HTTTYMSAPPKDM4EALDH1A1 | |
| SCHEMBL3778992 | 0.78 | HTT (0.64) | HTTHTR3AHRH4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353626-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2021-11-18 | — | — | US | disclosed |
| WO-2019204768-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353626-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | ADRB1, ADRB2, ADRA2B | HTT 4394/4885CYP1A1 2625/4885CYP1A2 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.